Goldman Sachs Group Inc Gracell Biotechnologies Inc. Transaction History

Goldman Sachs Group Inc

  • $555 Billion
  • Q1 2024

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024
BUY
$2.43 - $10.04 $5,180 - $21,405
2,132 Added 13.34%
18,112 $181,000
Q3 2023

May 14, 2024
SELL
$2.83 - $4.9 $6,033 - $10,446
-2,132 Reduced 11.77%
15,980 $46,000
Q3 2023

Nov 14, 2023
SELL
$2.83 - $4.9 $3,605 - $6,242
-1,274 Reduced 7.38%
15,980 $46,000
Q2 2023

May 14, 2024
SELL
$1.45 - $6.07 $311 - $1,305
-215 Reduced 1.23%
17,254 $65,000
Q2 2023

Aug 14, 2023
SELL
$1.45 - $6.07 $311 - $1,305
-215 Reduced 1.23%
17,254 $65,000
Q1 2023

May 14, 2024
SELL
$1.8 - $2.5 $5,385 - $7,480
-2,992 Reduced 14.62%
17,469 $32,000
Q1 2023

May 11, 2023
SELL
$1.8 - $2.5 $5,385 - $7,480
-2,992 Reduced 14.62%
17,469 $32,000
Q4 2022

May 14, 2024
SELL
$2.08 - $3.96 $5,944 - $11,317
-2,858 Reduced 12.26%
20,461 $47,000
Q4 2022

Feb 13, 2023
SELL
$2.08 - $3.96 $5,944 - $11,317
-2,858 Reduced 12.26%
20,461 $47,000
Q3 2022

May 14, 2024
SELL
$2.08 - $5.15 $1,994 - $4,938
-959 Reduced 3.95%
23,319 $75,000
Q3 2022

Nov 10, 2022
SELL
$2.08 - $5.15 $1,994 - $4,938
-959 Reduced 3.95%
23,319 $75,000
Q2 2022

May 14, 2024
BUY
$1.95 - $5.5 $12,023 - $33,913
6,166 Added 34.04%
24,278 $134,000
Q2 2022

Aug 15, 2022
SELL
$1.95 - $5.5 $156,274 - $440,775
-80,141 Reduced 76.75%
24,278 $134,000
Q1 2022

May 16, 2022
BUY
$1.83 - $5.52 $158,295 - $477,479
86,500 Added 482.73%
104,419 $243,000
Q4 2021

Feb 14, 2022
BUY
$5.65 - $14.9 $101,242 - $266,993
17,919 New
17,919 $108,000

Others Institutions Holding GRCL

# of Institutions
2
Shares Held
75.1K
Call Options Held
0
Put Options Held
0
View Full List

About Gracell Biotechnologies Inc.

GRCL Quotes by TradingView
  • Ticker GRCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,674,096
  • Description
  • Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...
More about GRCL
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email